In 2022, one of these anti-LAG3 mAbs, relatlimab, received FDA approval for treating unresectable or metastatic melanoma in combination with the anti-PD1 mAb nivolumab (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma) (9). The gene discussed is LAG3; the disease is melanoma.